REG - e-Therapeutics plc - Notification of Full Year Results Date

E-TherapeuticsAnnouncement

06/05/2021 07:00

RNS Number : 6972X
  
e-Therapeutics plc
  
06 May 2021
  
 

e-therapeutics plc
 
("e-therapeutics" or the "Company")
Notification of Full Year Results Date
e-therapeutics plc (AIM: ETX.L, "e-therapeutics'" or "the Company"), will announce its full year results for the year ended 31 January 2021 on Thursday 13 May 2021.
 



e-therapeutics plc








Ali Mortazavi, CEO


Tel: +44 (0)1993 883 125




Karl Keegan, CFO


www.etherapeutics.co.uk














SP Angel Corporate Finance LLP


Tel: +44(0)20 3470 0470




Nominated Adviser and Broker








Matthew Johnson/Caroline Rowe (Corporate Finance)








Vadim Alexandre/Rob Rees (Corporate Broking)

















 
 
About e-therapeutics plc
 
e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.
 
e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small subsets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.
 
e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NORBIGDUCSGDGBU